Rasi Electrodes (531233)
Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹28.59 |
| Market Cap | ₹90.12 Cr |
| P/E Ratio | 12.18 |
| ROCE | 10.85% |
| ROE | 9.94% |
| Dividend Yield | 0% |
| Profit Growth | 335.29% |
| Debt/Equity | — |
| Sales Growth | -10.76% |
| 52-Week Range | ₹9.27 — ₹28.59 |
| Sector | Industrial Manufacturing |
| Book Value | ₹11.88 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At surface, Rasi Electrodes looks like a classic value trap. The stock trades at ₹28.59, near its 52-week high, with a market cap of just ₹90 crore. The P/E of 12.18 appears reasonable until you inspect the underlying numbers. Sales are shrinking by 10.76% - the business is contracting. Profits jumped 335%, but that percentage is deceptive; it likely comes from a minuscule base. The latest quarter tells the real story: ₹17 crore sales, ₹1 crore net profit - a thin 5.9% margin. Return on equity of 9.94% and ROCE of 10.85% are mediocre. A wonderful business compounds capital at 20% plus with an economic moat; this has no discernible moat. Piotroski F-score of 6/9 offers some comfort, but there is no dividend—management isn't returning cash—and debt/equity is unlisted. As Graham said, you cannot value what you cannot measure. The PEG of 0.04 is mathematically absurd; it relies on that 335% profit growth repeating, which is improbable. Book value stands at ₹11.88, so paying ₹28.59 means a 2.41 times premium. The stock is at the top of its 52-week range (₹9.27-₹28.59), having tripled already. The easy money has likely been made. Without stable sales growth, sustainable margins, or a clearer capital structure, this remains a speculative punt, not an investment. I'd need to see evidence of a genuine turnaround before committing. In the words of Buffett, 'It's better to be unsure than wrong.'
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer